v3.26.3
Financing (Tables)
 9 Months Ended
Sep. 25, 2026
Debt Disclosure [Abstract]  
Components of Debt The components of the Company’s debt were as follows ($ in millions):
Outstanding Amount
Description and Aggregate Principal AmountSeptember 25, 2026December 31, 2025
Euro-denominated commercial paper (€4.1 billion and €933 million, respectively) (a)
$4,708 $1,097 
0.2% senior unsecured notes due 3/18/2026 (€1.3 billion) (the “2026 Biopharma Euronotes”) (b)
— 1,469 
2.1% senior unsecured notes due 9/30/2026 (€800 million) (the “2026 Euronotes”) (c)
912 940 
0.4773% senior unsecured notes due 4/9/2027 (CHF 250 million) (the “2027 CHF Notes”) (d)
301 315 
0.3% senior unsecured notes due 5/11/2027 (¥30.8 billion) (the “2027 Yen Notes”) (e)
196 196 
1.2% senior unsecured notes due 6/30/2027 (€600 million) (the “2027 Euronotes”) (f)
683 704 
0.45% senior unsecured notes due 3/18/2028 (€1.3 billion) (the “2028 Biopharma Euronotes”) (b)
1,422 1,466 
Floating rate senior unsecured notes due 4/29/2028 (€500 million) (the “2028 Floating Rate Notes”) (c)
568 — 
1.125% senior unsecured bonds due 12/08/2028 (CHF 210 million) (the “2028 CHF Bonds”) (d)
255 267 
0.8875% senior unsecured notes due 10/10/2029 (CHF 325 million) (the “2029 CHF Notes”) (d)
391 409 
2.6% senior unsecured notes due 11/15/2029 ($800 million) (the “2029 Biopharma Notes”) (b)
798 798 
2.5% senior unsecured notes due 3/30/2030 (€800 million) (the “2030 Euronotes”) (c)
912 940 
3.250% senior unsecured notes due 4/29/2030 (€750 million) (the “2030 Euronotes II”) (c)
850 — 
1.65% senior unsecured notes due 6/3/2031 (CHF 120 million) (the “2031 CHF Notes”) (g)
143 — 
Outstanding Amount
Description and Aggregate Principal AmountSeptember 25, 2026December 31, 2025
0.75% senior unsecured notes due 9/18/2031 (€1.8 billion) (the “2031 Biopharma Euronotes”) (b)
1,988 2,050 
0.65% senior unsecured notes due 5/11/2032 (¥53.2 billion) (the “2032 Yen Notes”) (e)
338 339 
1.88% senior unsecured notes due 6/3/2033 (CHF 137 million) (the “2033 CHF Notes II”) (g)
165 — 
1.265% senior unsecured notes due 10/10/2033 (CHF 325 million) (the “2033 CHF Notes”) (d)
390 408 
3.625% senior unsecured notes due 4/29/2034 (€750 million) (the “2034 Euronotes”) (c)
849 — 
2.10% senior unsecured notes due 6/3/2036 (CHF 221 million) (the “2036 CHF Notes”) (g)
265 — 
1.6249% senior unsecured notes due 10/9/2037 (CHF 225 million) (the “2037 CHF Notes”) (d)
270 282 
4.000% senior unsecured notes due 4/29/2038 (€1.0 billion) (the “2038 Euronotes”) (c)
1,131 — 
2.25% senior unsecured notes due 6/3/2038 (CHF 373 million) (the “2038 CHF Notes”) (g)
447 — 
1.35% senior unsecured notes due 9/18/2039 (€1.3 billion) (the “2039 Biopharma Euronotes”) (b)
1,413 1,456 
3.25% senior unsecured notes due 11/15/2039 ($900 million) (the “2039 Biopharma Notes”) (b)
893 892 
2.38% senior unsecured notes due 6/3/2041 (CHF 648 million) (the “2041 CHF Notes”) (g)
777 — 
4.375% senior unsecured notes due 9/15/2045 ($500 million) (the “2045 U.S. Notes”) (c)
500 500 
1.94% senior unsecured notes due 10/10/2045 (CHF 125 million) (the “2045 CHF Notes”) (d)
150 157 
2.51% senior unsecured notes due 6/3/2046 (CHF 502 million) (the “2046 CHF Notes”) (g)
601 — 
1.8% senior unsecured notes due 9/18/2049 (€750 million) (the “2049 Biopharma Euronotes”) (b)
846 873 
3.4% senior unsecured notes due 11/15/2049 ($900 million) (the “2049 Biopharma Notes”) (b)
891 891 
2.6% senior unsecured notes due 10/01/2050 ($1.0 billion) (the “2050 U.S. Notes”) (c)
983 983 
2.8% senior unsecured notes due 12/10/2051 ($1.0 billion) (the “2051 U.S. Notes”) (c)
986 985 
2.50% senior unsecured notes due 6/3/2056 (CHF 382 million) (the “2056 CHF Notes”) (g)
458 — 
Other2 1 
Total debt26,482 18,418 
Less: currently payable(2,094)(2)
Long-term debt$24,388 $18,416 
(a) Issued by Danaher Corporation or DH Europe Finance II S.a.r.l. (“Danaher International II”).
(b) Issued by Danaher International II.
(c) Issued by Danaher Corporation.
(d) Issued by DH Switzerland Finance S.a.r.l. (“Danaher Switzerland”).
(e) Issued by DH Japan Finance S.a.r.l. (“Danaher Japan”).
(f) Issued by DH Europe Finance S.a.r.l. (“Danaher International”).
(g) Issued by DH Masi Finance Inc. (“Danaher Masi”).
The following summarizes the key terms of the offerings in aggregate:
Aggregate Principal Amount (in millions)Stated Annual Interest RateMaturity DateIssue Price (as % of Principal Amount)
2028 Floating Rate Notes€500 Floating RateApril 29, 2028100.000 %
2030 Euronotes II7503.250 %April 29, 203099.934 %
2034 Euronotes7503.625 %April 29, 203499.918 %
2038 Euronotes1,0004.000 %April 29, 203899.953 %
Total Masimo Financing Euronotes€3,000 
2031 CHF Notes
CHF 120
1.65 %June 3, 2031100.000 %
2033 CHF Notes II
137
1.88 %June 3, 2033100.000 %
2036 CHF Notes
221
2.10 %June 3, 2036100.000 %
2038 CHF Notes
373
2.25 %June 3, 2038100.000 %
2041 CHF Notes
648
2.38 %June 3, 2041100.000 %
2046 CHF Notes
 502
2.51 %June 3, 2046100.000 %
2056 CHF Notes
382
2.50 %June 3, 2056100.000 %
Total Masimo Financing CHF Notes
CHF 2,383